Documents
Application Sponsors
NDA 213801 | ASTELLAS PHARMA GLOBAL DEV INC | |
Marketing Status
Application Products
001 | SUSPENSION;ORAL | 8MG/ML | 2 | MYRBETRIQ | MIRABEGRON |
FDA Submissions
TYPE 3; Type 3 - New Dosage Form | ORIG | 1 | AP | 2021-03-25 | PRIORITY |
Submissions Property Types
CDER Filings
ASTELLAS PHARMA GLOBAL DEV INC
cder:Array
(
[0] => Array
(
[ApplNo] => 213801
[companyName] => ASTELLAS PHARMA GLOBAL DEV INC
[docInserts] => ["",""]
[products] => [{"drugName":"MYRBETRIQ","activeIngredients":"MIRABEGRON","strength":"8MG\/ML","dosageForm":"SUSPENSION;ORAL","marketingStatus":"Prescription","te":"None","rld":"TBD","rs":"No"}]
[labels] => [{"actionDate":"03\/25\/2021","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/213801s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"03\/25\/2021","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form","reviewPriority":"PRIORITY","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/213801s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2021\\\/213801Orig1s000ltr.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2021-03-25
)
)